2005 related articles for article (PubMed ID: 12479591)
21. The colony-stimulating factors: use to prevent and treat neutropenia and its complications.
Komrokji RS; Lyman GH
Expert Opin Biol Ther; 2004 Dec; 4(12):1897-910. PubMed ID: 15571452
[TBL] [Abstract][Full Text] [Related]
22. Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience.
Renwick W; Pettengell R; Green M
BioDrugs; 2009; 23(3):175-86. PubMed ID: 19627169
[TBL] [Abstract][Full Text] [Related]
23. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
Smith TJ; Khatcheressian J; Lyman GH; Ozer H; Armitage JO; Balducci L; Bennett CL; Cantor SB; Crawford J; Cross SJ; Demetri G; Desch CE; Pizzo PA; Schiffer CA; Schwartzberg L; Somerfield MR; Somlo G; Wade JC; Wade JL; Winn RJ; Wozniak AJ; Wolff AC
J Clin Oncol; 2006 Jul; 24(19):3187-205. PubMed ID: 16682719
[TBL] [Abstract][Full Text] [Related]
24. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
Bohlius J; Reiser M; Schwarzer G; Engert A
Cochrane Database Syst Rev; 2004; (3):CD003189. PubMed ID: 15266474
[TBL] [Abstract][Full Text] [Related]
25. [OPERa Study].
Tesařová P
Klin Onkol; 2013; 26(6):425-33. PubMed ID: 24320592
[TBL] [Abstract][Full Text] [Related]
26. Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings.
Frampton JE; Yarker YE; Goa KL
Drugs; 1995 May; 49(5):767-93. PubMed ID: 7541335
[TBL] [Abstract][Full Text] [Related]
27. Colony-stimulating factors as an adjunct to chemotherapy in small cell lung cancer.
Urban T; Schuller MP; Lebeau B
Eur Respir J; 1996 Mar; 9(3):596-602. PubMed ID: 8730024
[TBL] [Abstract][Full Text] [Related]
28. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.
Liu Z; Doan QV; Malin J; Leonard R
Appl Health Econ Health Policy; 2009; 7(3):193-205. PubMed ID: 19799473
[TBL] [Abstract][Full Text] [Related]
29. Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia.
Rofail P; Tadros M; Ywakim R; Tadrous M; Krug A; Cosler LE
Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):699-709. PubMed ID: 23252353
[TBL] [Abstract][Full Text] [Related]
30. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.
Heuser M; Ganser A; Bokemeyer C; ; ;
Semin Hematol; 2007 Jul; 44(3):148-56. PubMed ID: 17631179
[TBL] [Abstract][Full Text] [Related]
31. Colony-stimulating factors for chemotherapy-induced febrile neutropenia.
Mhaskar R; Clark OA; Lyman G; Engel Ayer Botrel T; Morganti Paladini L; Djulbegovic B
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD003039. PubMed ID: 25356786
[TBL] [Abstract][Full Text] [Related]
32. A predictive model for neutropenia associated with cancer chemotherapy.
Lyman GH
Pharmacotherapy; 2000 Jul; 20(7 Pt 2):104S-111S. PubMed ID: 10905685
[TBL] [Abstract][Full Text] [Related]
33. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity.
Johnston EM; Crawford J
Semin Oncol; 1998 Oct; 25(5):552-61. PubMed ID: 9783594
[TBL] [Abstract][Full Text] [Related]
34. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer.
Repetto L; Biganzoli L; Koehne CH; Luebbe AS; Soubeyran P; Tjan-Heijnen VC; Aapro MS
Eur J Cancer; 2003 Nov; 39(16):2264-72. PubMed ID: 14556916
[TBL] [Abstract][Full Text] [Related]
35. Granulopoiesis-stimulating factors in the prevention for adverse effects in the therapeutic treatment of malignant lymphoma.
Bohlius J; Reiser M; Schwarzer G; Engert A
Cochrane Database Syst Rev; 2002; (4):CD003189. PubMed ID: 12519588
[TBL] [Abstract][Full Text] [Related]
36. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
[TBL] [Abstract][Full Text] [Related]
37. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.
Cooper KL; Madan J; Whyte S; Stevenson MD; Akehurst RL
BMC Cancer; 2011 Sep; 11():404. PubMed ID: 21943360
[TBL] [Abstract][Full Text] [Related]
38. [GM-CSF and G-CSF: cytokines in clinical application].
Ruef C; Coleman DL
Schweiz Med Wochenschr; 1991 Mar; 121(12):397-412. PubMed ID: 1709294
[TBL] [Abstract][Full Text] [Related]
39. Lecture: management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors.
Procopio G; Niger M; Testa I
Neurol Sci; 2011 Nov; 32 Suppl 2():S217-9. PubMed ID: 22002072
[TBL] [Abstract][Full Text] [Related]
40. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
Bohlius J; Reiser M; Schwarzer G; Engert A
Cochrane Database Syst Rev; 2004; (1):CD003189. PubMed ID: 14974009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
